Valbiotis S.A.
PAR: ALVAL.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sebastien Peltier
- Employees
- 44
- Headquarters
- Périgny, France
- IPO year
- 2017
- Market cap
- €22.4M
- Website
- https://www.valbiotis.com
Loading ALVAL…
Loading profile data…Frequently asked questions about ALVAL
What does Valbiotis S.A. (ALVAL.PA) do?
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 tha...
Where does ALVAL.PA trade?
Valbiotis S.A. (ALVAL.PA) trades on the Euronext Paris.
What sector is ALVAL.PA in?
Valbiotis S.A. (ALVAL.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Valbiotis S.A.?
Sebastien Peltier is the chief executive officer of Valbiotis S.A. (ALVAL.PA).
Where is Valbiotis S.A. headquartered?
Valbiotis S.A. is headquartered in France.
Does ALVAL.PA pay a dividend?
Valbiotis S.A. (ALVAL.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALVAL.PA go public?
Valbiotis S.A. (ALVAL.PA) completed its initial public offering in 2017.